
Laguna Tech USA, Inc. has raised $3.3M in total funding. The most recent round was Series A.
Laguna Tech USA, Inc. is headquartered in Irvine, CA.
Aortic regurgitation has no FDA-approved treatment device in the US, leaving patients reliant on medication (only for mild cases), open-heart surgery, or off-label TAVR devices that carry leak and embolization risks.
Laguna Tech is developing the ZETA Transcatheter Aortic Valve System, an investigational device now in first-in-human clinical trials, to treat both aortic regurgitation and aortic stenosis.
The page describes ZETA as the only balloon-expandable valve solution designed for both aortic regurgitation and stenosis, combining balloon-expandable and self-expanding features with six atraumatic arms and a design aimed at reducing pacemaker rates.
Laguna Tech USA is an Irvine-based transcatheter heart valve company led by CEO Gilbert Madrid; it has raised over $8M, including investment from MedTech Innovator.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.